Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
Vertex and Alnylam orphan drugs set for EU approvalOrphan drugs for cystic fibrosis and the hereditary rare disease hATTR are on course for European approval after Share XVertex and Alnylam orphan drugs set for EU approvalhttps://pharmaphorum.com/market-access-2/chmp-vertex-symkevi-alnylam-onpattro/
